<DOC>
	<DOCNO>NCT01171651</DOCNO>
	<brief_summary>The purpose pilot safety study evaluate safety tolerability JX-594 ( Pexa-Vec ) administer intravenously intratumorally prior standard sorafenib therapy .</brief_summary>
	<brief_title>A Study Recombinant Vaccinia Virus Prior Sorafenib Treat Unresectable Primary Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histological confirmation clinical/laboratory diagnosis primary hepatocellular carcinoma ( HCC ) Cancer surgically resectable cure Child Pugh A B Performance Score : KPS score ≥ 70 Platelet count ≥ 50,000 plts/mm3 Total bilirubin ≤ 2.5 x ULN AST , ALT &lt; 5.0 x ULN Acceptable coagulation status : INR ≤ 1.5 x ULN Acceptable kidney function : Serum creatinine &lt; 2.0 mg/dL Sorafenib naive refractory sorafenib therapy Tumor Status : At least one intrahepatic tumor , least ≥50 % total intrahepatic viable tumor mass , measurable CT injectable imagingguidance ( note : inject and/or viable tumor must previously untreated ≥20 % increase size since precede localregional treatment ) . Known contraindication sorafenib Pregnant nursing infant Significant immunodeficiency due underlie illness ( e.g . hematological malignancy , congenital immunodeficiency and/or HIV infection/AIDS ) and/or medication ( e.g . highdose systemic corticosteroid ) History exfoliative skin condition ( e.g . severe eczema , ectopic dermatitis , similar skin disorder ) stage require systemic therapy Clinically significant and/or rapidly accumulate ascites , pericardial and/or pleural effusion Severe unstable cardiac disease Current , know CNS malignancy Use antiplatelet anticoagulation medication Use follow antiviral agent : ribavirin , adefovir , cidofovir ( within 7 day prior first treatment ) , PEGIFN ( within 14 day prior first treatment ) . Patients household contact meet criterion unless alternate living arrangement make patient 's active dosing period 7 day follow last dose study medication : Pregnant nursing infant Children &lt; 12 month old History exfoliative skin condition stage require systemic therapy Significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Vaccinia</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>JX-594</keyword>
	<keyword>Jennerex</keyword>
	<keyword>Primary Hepatocellular Carcinoma</keyword>
	<keyword>Primary Liver Cancer</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Pexa-Vec</keyword>
</DOC>